Hit ENTER to search or ESC to close

Safety Profile

NeuroAiD is safe and well tolerated.

The safety profile of NeuroAiD is now well established. All clinical studies have reported NeuroAiD as a safe product, without severe adverse events and with only rare and transitory gastro-intestinal discomfort (e.g., nausea, vomiting) in subjects with sensitive digestive transit.

NeuroAiD has no impact on hepatic and renal functions, cardiovascular parameters, and other biological parameters1,2

NeuroAiD is not competing nor interacting with other medications. It can be safely combined to usual post-stroke medications or post-traumatic brain injury medications, and can also be added to other therapeutic products1,3.

No increase in the rates of delayed adverse events have been reported up to 2 years following a 3-month course with NeuroAiD4,5.

Always seek advice from your physician.

References

  • 1. . Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases. 2010;30:1-6.
  • 2. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases. 2008;25:450-456.
  • 3. Chen C, et al. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study. Stroke. 2013a;44:2093-2100
  • 4. Venketasubramanian N, et al. CHInese medicine NeuroAiD efficacy on stroke recovery – Extension study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases. 2015;39:309-318.
  • 5. Shahripour RB, et al. A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke. Chin J Integr Med. 2014;20(11): 812-817.